| 拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者的临床观察 |
| |
| 引用本文： | 邱源旺,黄利华,胡泰洪,周红燕,吴杭源,李燚光.拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者的临床观察[J].中国药房,2010(8):722-724. |
| |
| 作者姓名： | 邱源旺 黄利华 胡泰洪 周红燕 吴杭源 李燚光 |
| |
| 作者单位： | 江苏无锡市传染病医院; |
| |
| 摘 要： | 目的:探讨拉米夫定(LAM)联合阿德福韦酯(AVD)治疗乙型肝炎肝硬化失代偿期的疗效、安全性。方法:选择2006年6月～2008年6月门诊和住院乙型肝炎肝硬化失代偿期患者93例,随机分为3组。A组单用LAM(100mg·d-1);B组采用ADV(10mg·d-1);C组采用ADV(10mg·d-1)、LAM(100mg·d-1)联合治疗;3组均治疗52周。结果:治疗52周时3组患者间ALT水平、HBeAg阳性患者血清转换率比较,差异均无统计学意义(P>0.05);C组患者HBVDNA水平达到检测水平以下的百分率与B组患者比较,有显著性差异(P<0.05);3组间肝功能Child-Pugh评分比较差异无统计学意义(P>0.05)。3组患者的基因型耐药率分别为21.9%(7/32)、0、0。结论:乙型肝炎肝硬化失代偿期采用LAM联合ADV治疗更安全有效。
|
| 关 键 词： | 乙型肝炎 肝硬化 治疗 拉米夫定 阿德福韦酯 |
Clinical Observation of Lamivudine in Combination with Adefovir Dipivoxil in the Treatment of Decompensated Cirrhosis due to Hepatitis B |
| |
| QIU Yuan-wang,HUANG Li-hua,HU Tai-hong,ZHOU Hong-yan,WU Hang-yuan,LI Yi-guang.Clinical Observation of Lamivudine in Combination with Adefovir Dipivoxil in the Treatment of Decompensated Cirrhosis due to Hepatitis B[J].China Pharmacy,2010(8):722-724. |
| |
| Authors: | QIU Yuan-wang HUANG Li-hua HU Tai-hong ZHOU Hong-yan WU Hang-yuan LI Yi-guang |
| |
| Institution: | QIU Yuan-wang,HUANG Li-hua,HU Tai-hong,ZHOU Hong-yan,WU Hang-yuan,LI Yi-guang(Jiangsu Wuxi Infectious Disease Hospital,Wuxi 214000,China) |
| |
| Abstract: | OBJECTIVE:To evaluate the efficacy and safety of lamivudine and adefovir dipivoxil in the treatment of decompensated cirrhosis due to chronic hepatitis B.METHODS:A total of 93 patients with decompensated cirrhosis due to chronic hepatitis B from Jun.2006 to Jun.2008 were randomly assigned into three groups.Group A received lamivudine,group B received adefovir dipivoxil and group C received adefovir dipivoxil in combination with lamivudine for 52 weeks.RESULTS:There were no significant difference in the leve... |
| |
| Keywords: | Hepatitis B Chronic Therapy Lamivudine Adefovir dipivoxil |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
